RasGRP1 stimulation enhances ubiquitination and endocytosis of the sodium-chloride cotransporter
Benjamin Ko, Erik-Jan Kamsteeg, Leslie L. Cooke, Lauren N. Moddes, Peter M. T. Deen and Robert S. Hoover

This article cites 45 articles, 30 of which can be accessed free at:
http://ajprenal.physiology.org/content/299/2/F300.full.html#ref-list-1

This article has been cited by 3 other HighWire hosted articles

WNK4 inhibits NCC protein expression through MAPK ERK1/2 signaling pathway
Bo Zhou, Dexuan Wang, Xiuyan Feng, Yiqian Zhang, Yanhui Wang, Jieqiu Zhuang, Xuemei Zhang, Guangping Chen, Eric Delpire, Dingying Gu and Hui Cai
[Abstract] [Full Text] [PDF]

Nedd4-2 Modulates Renal Na⁺-Cl⁻ Cotransporter via the Aldosterone-SGK1-Nedd4-2 Pathway
Juan Pablo Arroyo, Dagmara Lagnaz, Caroline Ronzaud, Norma Vázquez, Benjamin S. Ko, Lauren Moddes, Dorothée Ruffieux-Daidié, Pierrette Hausel, Robert Koesters, Baoli Yang, John B. Stokes, Robert S. Hoover, Gerardo Gamba and Olivier Staub
JASN, September , 2011; 22 (9): 1707-1719.
[Abstract] [Full Text] [PDF]

Constitutive endocytosis and recycling of NKCC2 in rat thick ascending limbs
Gustavo R. Ares and Pablo A. Ortiz
[Abstract] [Full Text] [PDF]

Updated information and services including high resolution figures, can be found at:
http://ajprenal.physiology.org/content/299/2/F300.full.html

Additional material and information about AJP - Renal Physiology can be found at:
http://www.the-aps.org/publications/ajprenal

This information is current as of July 11, 2012.
RasGRP1 stimulation enhances ubiquitination and endocytosis of the sodium-chloride cotransporter

Benjamin Ko,1 Erik-Jan Kamsteeg,2 Leslie L. Cooke,1 Lauren N. Moddes,1 Peter M. T. Deen,2 and Robert S. Hoover1

1Department of Medicine, University of Chicago, Chicago, Illinois; and 2Department of Physiology, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands

Submitted 31 July 2009; accepted in final form 12 April 2010

RasGRP1 stimulation enhances ubiquitination and endocytosis of the sodium-chloride cotransporter. Am J Physiol Renal Physiol 299:F300–F309, 2010. First published April 14, 2010; doi:10.1152/ajprenal.00441.2009.—The sodium-chloride cotransporter (NCC) is the principal salt-absorptive pathway in the distal convoluted tubule. Recently, we described a novel pathway of NCC regulation in which phorbol esters (PE) stimulate Ras guanyl-releasing protein 1 (RasGRP1), triggering a cascade ultimately activating ERK1/2 MAPK and decreasing NCC cell surface expression (Ko B, Joshi LM, Cooke LL, Vazquez N, Musch MW, Hebert SC, Gamba G, Hoover RS. Proc Natl Acad Sci USA 104: 20120–20125, 2007). Little is known about the mechanisms which underlie these effects on NCC activity. Regulation of NCC via changes in NCC surface expression has been reported, but endocytosis of NCC has not been demonstrated. In this study, utilizing biotinylation, internalization assays, and a dynamin dominant-negative construct, we demonstrate that the regulation of NCC by PE occurs via an enhancement in internalization of NCC and is dynamin dependent. In addition, immunoprecipitation of NCC and subsequent immunoblotting for ubiquitin showed increased ubiquitination of NCC with phorbol ester treatment. MEK1/2 inhibitors and gene silencing of RasGRP1 indicated that this effect was dependent on RasGRP1 and ERK1/2 activation. Inhibition of ubiquitination prevents any PE-mediated decrease in NCC surface expression as measured by biotinylation or NCC activity as measured by radiotracer uptake. These findings confirmed that the PE effect on NCC is mediated by endocytosis of NCC. Furthermore, ubiquitination of NCC is essential for this process and this ubiquitination is dependent upon RasGRP1-mediated ERK1/2 activation.

ubiquitin; ERK1/2; MAPK

THE THIАЗIDE-SENSITIVE sodium-chloride cotransporter (NCC), encoded by the SLC12A3 gene, in the distal convoluted tubule (DCT) of the kidney plays a key role in renal salt handling and blood pressure regulation. Residing in the DCT, NCC is responsible for the reabsorption of 5–10% of filtered sodium and chloride in the kidney (7). The cotransporter’s importance in sodium balance, and therefore blood pressure regulation, is demonstrated not only by the efficacy of thiazide diuretics but also by the hypotension seen with loss of NCC function (Gitelman’s syndrome) and the hypertension seen with increases in NCC activity (familial hyperkalemic hypertension or FHHI) (19, 27, 39). Recently, we identified a regulatory pathway for NCC, demonstrating that phorbol esters (PE) regulate NCC activity (12). Importantly, PE act as functional analogs of diacylglycerol (DAG) and do not act on NCC in this system via protein kinase C but instead mediate activation of Ras guanyl-releasing protein 1 (RasGRP1), ultimately leading to increased ERK1/2 MAPK activation. Following activation by DAG, RasGRP1 activates the small G protein Ras (specifically the isoform H-Ras in this system) by causing release of GDP from Ras. Ras then binds and is activated by GTP. Ras activates Raf, the first kinase in the ERK1/2 MAPK pathway. Raf then phosphorylates and activates MEK1/2, which in turn phosphorylates and activates ERK1/2. Activation of the Ras-MEK-ERK1/2 MAPK cascade by PE/RasGRP1 is necessary for the decreases in NCC activity seen with PE administration (12).

While the functional effect on NCC activity by PE correlates with a decrease in the amount of NCC expressed on the cell surface, the mechanisms by which this may occur are not known (12). Investigators exploring the modulation of NCC by other agents have found evidence that forward trafficking appears to be regulated (3, 9, 33). Whole animal studies have demonstrated the existence of a subapical pool of NCC and have shown a redistribution of NCC from the cell surface to this subapical pool under inhibition of the angiotensin-converting enzyme, but it is not clear whether this redistribution represents decreased forward trafficking or increased endocytosis (23, 24). Details of how these cell-trafficking events occur need to be further explored.

The role of ERK1/2 activation in the DAG/PE effect on NCC activity is of particular interest as ERK1/2 activation has been linked to ubiquitination of a number of proteins, including the epithelial sodium channel (ENaC) (1a, 13, 15, 18, 26, 28). Ubiquitin is an 8-kDa highly conserved protein that covalently attaches to lysine residues of target proteins either singly (monoubiquitination) or in polymerized chains (polyubiquitination). This attachment can tag a protein for endocytosis and/or degradation and is accomplished via the enzymes E1, E2, and E3, which act to transfer ubiquitin molecules to the target protein. In some systems, regulating the ubiquitination of a protein allows for modulation of that protein’s endocytosis and/or degradation. ERK1/2 MAPK has clearly been shown to play a role in the regulation of ubiquitination and subsequent degradation in a variety of settings, from the regulation of ENaC to programmed cell death (1a, 13, 15, 18, 26, 28).

We therefore theorized a potential role for ERK1/2 MAPK activation in regulating ubiquitination and sought to assess the role of ubiquitination in cell-trafficking events that result in decreased NCC surface expression. In this study, using both a mammalian cell model with native NCC function and a heterologous mammalian expression system, we demonstrate that the regulation of NCC by DAG/PE occurs due to a decrease in NCC surface expression via enhanced, dynamin-dependent endocytosis. Furthermore, we show that ubiquitination of NCC...
is essential for this process and that this ubiquitination is dependent upon RasGRP1-mediated ERK1/2 activation.

**MATERIALS AND METHODS**

**Materials.** Materials were purchased from Sigma-Aldrich (St. Louis, MO) unless stated otherwise. The mouse DCT (mDCT) cells were a gift from Dr. Peter Friedman. The K44A dynamin construct was a gift from Dr. Eugene Chang. The Madin-Darby canine kidney (MDCK) cell lines expressing Flag-NCC were a gift from Dr. René Bindels. The NCC antibody was a gift from Dr. Mark Knepper.

**Cell culture and treatments.** mDCT cells were plated on cell culture dishes and grown in high glucose culture medium containing a 50:50 mix of DMEM/F12, 5% heat-inactivated fetal bovine serum, and 1% penicillin/streptomycin/neomycin (P/S/N) at 37°C. Experiments were conducted when the cells reached 90–95% confluence. MDCK cell culture, immunocytchemistry, and the collection of images were performed as described elsewhere (5). Cells were treated with TPA (10−7 M) in culture medium where indicated and for the indicated time intervals.

**Assessment of NCC function in mDCT cells.** mDCT cells were seeded in 12-well plates and prepared as described. The cells were then incubated in a serum-free, preuptake medium (130 mM Na gluconate, 2 mM K gluconate, 1.0 mM Ca gluconate, 1 mM Mg gluconate, 5 mM HEPES/Tris pH 7.4, 1 mM amiloride, 0.1 mM bumetanide) for 30 min. For studies examining forward trafficking, the cells were incubated with 10 μM befreldin A (BFA) for 1 h. During this time period, the cells were treated with the various agents being studied [100 nM TPA for 15 min and either 10 nM U0126 or vehicle (DMSO) for 15 min]. The medium was then changed to a 22Na+−containing medium (140 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES/Tris pH 7.4, 1 mM amiloride, 0.1 mM bumetanide, 0.1 mM benzamil, 1 mM ouabain, and 1 μCi/ml of 22Na+−) with or without thiazide (0.1 mM benzamil, 1 mM ouabain, and 1 μCi/ml of 22Na+−) with or without thiazide (0.1 mM metolazone) and incubated for 20 min. Tracer uptake was then stopped via washes with ice-cold wash buffer. For studies examining internalization, the medium (as above, without 22Na+−) was added, and the cells were incubated for 20 min each with ice-cold 100 mM 2-sodium mercaptoethanesulfonic acid (MesNa) in 100 mM NaCl, 1 mM EDTA, 50 mM Tris (pH = 8.6), and 0.2% BSA. Excess MesNa was quenched for 10 min with ice-cold 120 mM iodoacetic acid in PBS-CM, and cells were lysed as for biotinylation. Subsequently, all lysates were precleared by centrifugation at 14,000 g and incubated with 30-μl aliquots of prewashed streptavidin-conjugated beads (Pierce) for 16 h. Finally, the beads were washed twice with high-salt buffer [500 mM NaCl, 5 mM EDTA, 50 mM Tris (pH = 7.5), 0.1% Triton X-100], twice with lysis buffer, and once with 10 mM Tris (pH = 7.5) and resuspended in 30 μl Laemmli buffer.

**Immunoblotting.** For mDCT cells, a 7.5% polyacrylamide gel was used. Proteins were transferred electrophoretically to polyvinylidene difluoride membranes. After blocking with 3% BSA, the membranes were probed with corresponding primary antibodies [ubiquitin (Cell Signaling) 1:1,000, anti-RasGRP1 (Cell Signaling), dilution 1:200, or anti-NCC (Knepper) dilution 1:50,000)] overnight at 4°C. The blots were washed in TBST. Signal detection for RasGRP1, NCC, and ubiquitin was done using IRDye800 anti-mouse IgG antibody, IRDye800 rabbit anti-goat IgG antibody, IRDye800 rabbit anti-rabbit antibody, and IRDye680 goat anti-mouse dilution (1:10,000, Rockland Immunobiochemicals) and subsequent scanning of the membrane by an Odyssey Infrared Imager. Intensity of the protein bands was analyzed by using Odyssey Infrared Imaging Software (Li-Cor Biosciences). For MDCK cells, PAGE and blotting, blocking, antibody incubation, and chemiluminescence of the membranes were performed as described (11). Ubiquitin (Zymed, San Francisco, CA) antibodies were diluted 1:250, followed by 1:10,000-diluted biotinylated anti-mouse IgG’s (Jackson Laboratories) and by 1:8,000-diluted streptavidin-peroxidase. Mouse Flag antibodies (Zymed) were diluted 1:1,000.

**Immunocytchemistry.** Essentially, immunocytchemistry and collection of images were performed as described previously (5), except that cells were not permeabilized with 1% Triton X-00 but with 1% saponin. Mouse Flag antibodies were diluted 1:100.

**Immunoprecipitation.** MDCK cells were grown to confluence, treated as indicated, lysed [1% Triton X-100, 150 mM NaCl, 25 mM HEPES (pH = 7.4), supplemented with protease inhibitors and 20 mM NEM] and spun down to remove nonsolubilized material. Fifteen-microLiter equivalents of protein A-agarose were preincubated with either rabbit FLAG antibodies in IPP500 [500 mM NaCl, 10 mM Tris (pH = 8.0), 0.1% NP-40, 0.1% Tween 20], rabbit antibodies to RasGRP1 (Santa Cruz Biotechnologies), or rabbit antibodies to NCC and 0.1% BSA, and washed three times with IPP500. The precleared lysates were incubated for 16 h at 4°C with the antibody-bound protein A beads. The beads were washed three times with lysis buffer, and proteins were eluted using 15 μl Laemmli buffer.

**Dominant-negative dynamin transfected.** mDCT cells were grown to 80% confluence in a medium containing a 50:50 mix of DMEM/F12 plus 5% heat-inactivated FBS, and 1% P/S/N. The heme agglutinin (HA)-K44A dynamin construct or wild-type dynamin was trans-
siently transfected into these cells using GenePorter Transfection Reagent per the manufacturer’s protocol (Genlantis). Confirmation of transfection was achieved by immunoblotting using a rabbit anti-dynamin antibody (1:1,000 dilution, Cell Signaling).

Gene silencing. mDCT cells were grown to 80% confluence in a medium containing a 50:50 mix of DMEM/F12 plus 5% heat-inactivated FBS, and 1% P/S/N. Small interfering (si) RNA specific for RasGRP1 (Dharmacon) was transfected into these cells using GeneSilencer siRNA Transfection Reagent per the manufacturer’s protocol (Genlantis). Nontargeting siRNA differing by a single base pair from the siRNA for RasGRP1 (Dharmacon) was used as a control (1).

ERK1/2 phosphorylation assay. mDCT cells grown to 80% confluence after transfection with siRNA were incubated for 30 min in a preuptake medium. During this time period, the cells were treated with 100 nM TPA for 15 min. Cells were subsequently lysed in 1 ml of lysis buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 1 tablet of Complete protease inhibitors (Roche). The lysates were homogenized by sonication on ice. Protein determination and immunoblotting were then performed as described above using antibodies for phospho-ERK1/2 (1:1,000, Cell Signaling) and ERK1/2 (1:200, Santa Cruz Biotechnology). Densitometry was then performed, and relative densitometry was reported by expressing each group as a fraction of its phosphorylated form over total ERK1/2. Controls were then normalized to 1.

Statistical analysis. Statistical analysis was performed using the SigmaStat software package (Systat, San Jose, CA). Data was analyzed for statistical significance using ANOVA (Holm-Sidak). A P value of <0.05 was taken as statistically significant.

RESULTS

PE enhance endocytosis of NCC. We previously demonstrated that the reduction of NCC activity with DAG/PE stimulation was tied to a decrease in NCC surface expression (12). To assess the mechanism by which this occurs, we performed internalization assays on mDCT cells. In this assay, cell surface proteins are first biotinylated at 4°C before the cells are rewarmed and treated with TPA. The cells are then treated with MesNa, a cell-impermeable acid which cleaves the biotin-protein attachments. Since MesNa is cell impermeable, any remaining biotinylated protein represents internalized proteins. This protocol is a well-established method for assessing internalization (5, 11, 21, 34). As shown in Fig. 1, treatment with MesNa virtually eliminated surface-expressed NCC (control with MesNa at time 0) compared with vehicle (control at time 0 without MesNa). Increased internalization of NCC with exposure to TPA (100 nM) vs. control (vehicle, DMSO) was evident as early as 10 min after exposure (P < 0.01). Over this time, total cellular NCC remained constant in both groups, suggesting that NCC degradation does not occur in response to PE in this time frame. These findings are consistent with images obtained using MDCK cells stably transfected with Flag-tagged NCC subjected to immunocytochemistry and confocal microscopy. These MDCK-Flag NCC cells were treated with 100 nM TPA for 15 and 45 min before fixation and immunocytochemistry. Subsequent confocal microscopy in both the XY and XZ planes showed decreased apical NCC surface expression 15 and 45 min after treatment with TPA (Fig. 1B).

Dynamin is a GTPase critical for endocytosis, an effect inhibited by the dominant-negative dynamin mutant K44A (4). Therefore, to demonstrate that PE-induced NCC endocytosis is dynamin dependent, mDCT cells were transfected with HA-tagged dynamin dominant-negative construct to assess the dynamin dependence of the DAG/PE effect. Mock transfected cells behaved similarly to those observed in our previous experiments, resulting in a 76 ± 4% reduction in NCC surface expression with TPA compared with control, but mDCT cells expressing the dominant-negative dynamin showed no change in NCC surface expression with TPA administration (P < 0.05 vs. vehicle, Fig. 2). Cells transfected with wild-type dynamin behave as control. Taken together, these data indicate that the DAG/PE effect upon NCC occurs via enhancing dynamin-dependent endocytosis of surface NCC.

PE do not affect forward trafficking of NCC. While these data show that TPA clearly enhances endocytosis, NCC has been shown in other systems to be regulated via affecting
forward trafficking of NCC to the plasma membrane (3, 9, 33). Therefore, we examined the ability of TPA to affect forward trafficking of NCC. BFA (10 \mu M) was used to inhibit forward trafficking of NCC. BFA blocks transport of new proteins from the endoplasmic reticulum/Golgi to the plasma membrane. As shown in Fig. 3A, NCC surface expression decreased by 24 ± 3% over control after 1 h of BFA incubation, indicating continued endocytosis with inhibition of exocytosis (P < 0.05). At 3 h, NCC surface expression decreased by 52 ± 4% over control (Fig. 3A, P < 0.05). This is consistent with previously published reports of BFA inhibition of NCC forward trafficking, which demonstrated an NCC surface half-life

---

**Fig. 3. Role of forward trafficking in TPA effect on surface expression and NCC activity.** A: mDCT cells were grown to confluence, transfected with hemeagglutinin-tagged with either wild-type (DW) or K44A (DN) dynamin as described, then treated with 100 nM TPA (T) or vehicle (C) for 15 min before labeling with biotin at 4°C. Biotinylated (cell surface) proteins were recovered using streptavidin-agarose and immunoblotted for NCC. NC, no biotin control. Accompanying densitometry is shown (n = 4). *P < 0.05 compared with time 0. B: mDCT cells prepared as above were treated with 10 \mu M BFA or vehicle for 1 h before treatment with 100 nM TPA. Cells were then labeled with biotin at 4°C. Biotinylated (cell surface) proteins were recovered using streptavidin-agarose and immunoblotted for NCC. C, vehicle; B, BFA alone; T, TPA alone; BT, BFA plus TPA. Accompanying densitometry is shown (n = 4). *P < 0.05 compared with control. #P < 0.05 compared with BFA group. C: mDCT cells were grown to confluence, treated with BFA or vehicle for either 1 or 3 h, and then treated with 100 nM TPA (T) or vehicle for 15 min. Cells were subsequently incubated in uptake medium with \(^{22}\text{Na}^-\) and either vehicle or 1 mM metolazone. Radioactive uptake was determined as in MATERIALS AND METHODS. Thiazide-sensitive uptake was calculated as the difference in radio-tracer uptake between the metolazone-containing and the metolazone-free groups. C, control; B1, BFA 1 h; B3, BFA 3 h; T, TPA; B1+T, BFA 1 h plus TPA; B3+T, BFA 3 h plus TPA (n = 4). *P < 0.05 compared with control. #P < 0.05 compared with control, B1, or B3 (no statistical difference among T, B1+T, and B3+T).
of ∼3 h (33). NCC activity showed a similar decrease with BFA treatment, 12.4 ± 3.2% of control at 1 h and 45.3 ± 1.3% of control at 3 h (Fig. 3C, P < 0.05). In mDCT cells treated with a 1-h BFA incubation, TPA treatment essentially eliminated NCC surface expression (Fig. 3B). This was similar to TPA alone, indicating that TPA does not significantly act on NCC by affecting forward trafficking (33). This is in contrast to WNK4’s effect on NCC, which acts via inhibition of forward trafficking (3, 9, 33). NCC activity was essentially eliminated by TPA compared with control by TPA alone or in groups treated with BFA for either 1 or 3 h (Fig. 3C, P < 0.05)

There were no significant differences in surface expression between the TPA alone and the two BFA- and TPA-treated groups. This demonstrates that PE do not act on NCC via forward trafficking but instead via enhanced endocytosis.

**PE enhance ubiquitination of NCC.** As previously discussed, we theorized that a potential signal for endocytosis of NCC was ubiquitination. To investigate a possible role for ubiquitin in mediating internalization of NCC in response to DAG/PE, we assessed the ability of TPA to augment ubiquitination of NCC. mDCT cells were treated with 100 nM TPA for varying time periods minutes before lysis and immunoprecipitation. Immunoblotting showed a significant increase in ubiquitinated NCC by 10 min of TPA treatment and a nearly fivefold increase in ubiquitinated NCC over control after 20 min of TPA treatment (P < 0.01 by ANOVA, n = 4, Fig. 4A). Ubiquitination of NCC was also assessed in the MDCK Flag-NCC cell line. These cells were treated with 100 nM TPA for 5 min, lysed, and immunoprecipitated with anti-FLAG antibody. Subsequent immunoblotting for ubiquitin clearly demonstrated a band centered around 140 kDa, representing ubiquitination of NCC (Fig. 4B). These data indicate that NCC is ubiquitinated after treatment with the PE TPA.

**Ubiquitination of NCC is dependent on RasGRP1-mediated ERK1/2 activation.** As we have previously demonstrated that PE enhance ubiquitination of NCC, we utilized a chemical inhibitor of ubiquitination, 4-[4-(5-Nitro-furan-2-ylmethylene)-3,4-dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester (UBEI-41). UBEI-41 is a benzoic acid ethyl ester that inhibits the action of the E1 enzyme, inhibiting ubiquitination by preventing ubiquitin attachment (42). Incubation of mDCT cells with 50 μM UBEI-41 for 15 min eliminates ubiquitination for NCC by affecting forward trafficking (33). UBEI-41 had no effect on ERK1/2 activation by TPA. To directly assess the role of NCC ubiquitination in DAG/PE regulation of NCC, we utilized a chemical inhibitor of ubiquitination, 4-[4-(5-Nitro-furan-2-ylmethylene)-3,4-dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester (UBEI-41). UBEI-41 is a benzoic acid ethyl ester that inhibits the action of the E1 enzyme, inhibiting ubiquitination by preventing ubiquitin attachment (42).

To verify the involvement of RasGRP1 in this process, mDCT cells were transfected with siRNA specific for RasGRP1. Cells treated in this manner were again treated with TPA and assayed for NCC ubiquitination as above. Cells transfected with nonspecific siRNA continued to demonstrate a nearly fivefold increase in ubiquitinated NCC (P < 0.01). A 94 ± 5% reduction in RasGRP1 expression was achieved (Fig. 5B, P < 0.05 compared with transfection with nontargeting siRNA), and in these cells TPA did not have an effect on ubiquitination of NCC compared with cells transfected with nontargeting siRNA (Fig. 5A). These data indicate that TPA’s ability to enhance NCC ubiquitination is dependent upon activation of RasGRP1 and ERK1/2.

**Inhibition of ubiquitination by an E1 inhibitor does not affect ERK1/2 activation by TPA.** To directly assess the role of NCC ubiquitination in DAG/PE regulation of NCC, we utilized a chemical inhibitor of ubiquitination, 4-[4-(5-Nitro-furan-2-ylmethylene)-3,4-dioxo-pyrazolidin-1-yl]-benzoic acid ethyl ester (UBEI-41). UBEI-41 is a benzoic acid ethyl ester that inhibits the action of the E1 enzyme, inhibiting ubiquitination by preventing ubiquitin attachment (42). Incubation of mDCT cells with 50 μM UBEI-41 for 15 min eliminates ubiquitination of NCC in response to TPA (Fig. 6A). UBEI-41 had no effect on ERK1/2 activation by TPA, with the combination of TPA and UBEI-41 increasing ERK1/2 phosphorylation by 204 ± 9 compared with 205 ± 6% for TPA alone (P < 0.05 for either vs. vehicle by ANOVA, n = 4, Fig. 6B). Therefore, UBEI-41 effectively inhibits ubiquitination of NCC but has no effect on ERK1/2 activation by PE. Since RasGRP1 and ERK1/2 activation is necessary for TPA to enhance the ubiquitination of NCC and inhibition of ubiquitination has no effect on ERK1/2 activation, this demonstrates that ERK1/2 phosphorylation and activation lie upstream of ubiquitination of NCC.
Inhibition of ubiquitination prevents effect of TPA on NCC activity. To determine whether ubiquitination of NCC was necessary for PE to modulate NCC surface expression and activity, the ubiquitin inhibitor UBEI-41 was used. In mDCT cells treated with TPA and biotinylated as described previously, the addition of UBEI-41 prevented the decrease in NCC surface expression seen with TPA alone (unchanged from baseline for TPA and UBEI-41 vs. 73 ± 4% decrease from baseline for TPA alone, Fig. 7A).

The impact of ubiquitination upon NCC function was then assessed by measuring NCC activity by 22Na radiotracer uptake assay in the presence of 50 μM UBEI-41. Treatment with UBEI-41 for 15 min did not significantly alter the baseline activity.

Fig. 6. Inhibition of ubiquitination does not affect TPA-mediated ERK1/2 phosphorylation. A: mDCT cells were grown to confluence, treated with 100 nM TPA (T) in the presence or absence of UBEI-41 (U) for 15 min before lysis in RIPA buffer. TU, TPA + UBEI-41. NCC was then immunoprecipitated using NCC antibodies before immunoblotting with anti-ubiquitin or anti-NCC antibodies; n = 4. B: cells treated as described in A were lysed and immunoblotted for phospho-ERK1/2 and ERK1/2; n = 4. C, control. *P < 0.05.

The impact of ubiquitination upon NCC function was then assessed by measuring NCC activity by a 22Na radiotracer uptake assay in the presence of 50 μM UBEI-41. Treatment with UBEI-41 for 15 min did not significantly alter the baseline activity.

Fig. 5. NCC ubiquitination with TPA treatment with inhibition of the Ras guanyl-releasing protein 1 (RasGRP1) ERK1/2 pathway. A: mDCT cells were grown to confluence and treated with 10 nM U0126 (U) or vehicle (DMSO, C). Cells were then treated with 100 nM TPA (T) or vehicle (DMSO, C) for 15 min before lysis in RIPA buffer. NCC was then immunoprecipitated using NCC antibodies before immunoblotting with anti-ubiquitin (Ub) or anti-NCC antibodies (NCC); n = 4. B: cells treated as described in A were lysed and immunoblotted for RasGRP1 expression and nontargeting small interfering (si) RNA (S) as described. Suppression of RasGRP1 expression is shown (n = 4). *P < 0.01. C: mDCT cells were grown to confluence and transfected with siRNA for RasGRP1 (S) or nontargeting small interfering (si) RNA (N) as described. Suppression of RasGRP1 expression is shown in immunoblot (P < 0.05, n = 4). Cells were then treated with 100 nM TPA (T) or vehicle (DMSO, C) for 15 min before lysis in RIPA buffer. NCC was then immunoprecipitated before immunoblotting with anti-ubiquitin or anti-NCC antibodies as above. TS, TPA + siRNA for RasGRP1. Accompanying densitometry is shown (n = 4). *P < 0.05.

AJP-Renal Physiol • VOL 299 • AUGUST 2010 • www.ajprenal.org
activity of NCC (Fig. 7B). However, UBEI-41 did significantly alter the response to TPA, with TPA and UBEI-41 in combination causing no change in NCC activity while TPA alone resulted in a 87 ± 8% decrease, indicating that ubiquitination of NCC is essential in decreasing NCC activity (P < 0.01 vs. vehicle, n = 6). These data show that this is accomplished by PE-mediated activation of RasGRP1, triggering Ras, MEK1/2, and ERK1/2 MAPK activation. This ERK1/2 MAPK activation then leads to enhanced ubiquitination of NCC. The increased ubiquitinated NCC leads to increased endocytosis of NCC and decreased cell surface expression, ultimately leading to decreased NCC activity.

**DISCUSSION**

PE-mediated ERK1/2 activation almost completely suppresses NCC activity as measured by $^{22}$Na$^+$ studies, accompanied by an ~70% reduction in surface expression as measured by biotinylation (12). This finding was echoed by immunocytochemical staining and confocal microscopy of MDCK-FLAG NCC cells showing decreased apical cell surface expression with exposure to TPA (Fig. 1). In contrast to WNK4’s reported effects on NCC, the PE do not appear to affecting forward trafficking of the cotransporter (3, 9, 33). Additionally, this work demonstrates that ERK1/2 MAPK activation by a PE/RasGRP1-mediated pathway triggers endocytosis of NCC. Tracking internalized NCC after PE treatment using biotinylation and subsequent treatment with MesNa showed a marked increase in internalized NCC in response to PE treatment, indicating endocytosis. The dynamin dependence of this finding was confirmed by introducing the dominant-negative dynamin mutant K44A into the system, which inhibited that change in NCC surface expression, indicating that PE’s effect was via dynamin-dependent endocytosis of NCC. Using BFA to inhibit Golgi transport does not inhibit the effect of PE on surface expression, indicating that PE work primarily by stimulating endocytosis and not by affecting forward trafficking. To our knowledge, this is the first report of endocytosis of NCC.

In our mDCT cell model, NCC appears to be ubiquitinated and run as two ubiquitinated species (Fig. 4A). This is the first report of ubiquitination of NCC. Inhibition of ubiquitination with an E1 enzyme inhibitor eliminates the top band. This suggests that NCC may be constitutively ubiquitinated, with a second ubiquitination event mediated by PE stimulation. It is unclear whether this ubiquitination event represents short-chain polyubiquitination at the previous site or multiburiquitination at different sites, and this issue merits further study. Of note, while baseline ubiquitination is observed in the mDCT model, the transfected MDCK model does not appear to demonstrate significant baseline ubiquitination. This may be due to an alteration in baseline ubiquitination, due to a number of potential mechanisms. In ENaC, alterations in baseline ubiquitination were seen depending on the level of expression of the E3 ligase Nedd4–2 (44). These models may simply have varying expressions of the relevant E3 ligase, or for that matter a deubiquitinating enzyme (DUB), resulting in the differences in baseline ubiquitination. Determining the mechanism behind these differences merits future study.

In a series of whole animal studies conducted by Sandberg et al. (23, 24), NCC was shown by immunoelectron microscopy to reside in an apical (cell surface expressed) pool as well as in subapical vesicles. NCC appeared to redistribute within these pools in response to the administration of an angiotensin-converting enzyme inhibitor or angiotensin II infusion. These studies, however, could not distinguish between a decrease in forward trafficking and insertion of NCC in the plasma.
membrane or an increase in endocytosis of NCC from the plasma membrane (23, 24). Experiments using the Xenopus laevis expression system to coexpress WNK4 and enhanced green fluorescent protein-NCC have demonstrated reduced NCC cell surface expression in the presence of WNK4, a kinase associated with the form of genetic hypertension known as FHHI (40, 41). In this case, further studies demonstrated that the addition of a K44A dynamin-dominant negative did not affect WNK4 inhibition of NCC cell surface expression. This ultimately led to work using inhibitors of Golgi transport and lysosomal degradation to show that WNK4 likely impacted NCC surface expression by impeding forward trafficking to the cell surface and enhancing lysosomal degradation (3, 9, 33).

While endocytosis of NCC has not been previously demonstrated, there are numerous examples of transport protein regulation via dynamin-dependent endocytosis, and ERK1/2 MAPK has also been shown to mediate changes in surface expression of ion transport proteins (10, 29, 35, 36, 43). We previously demonstrated that the RasGRP1-ERK1/2 MAPK pathway was essential for decreasing NCC surface expression and activity associated with DAG/PE (12). The PE TPA, a functional analog of DAG, activates RasGRP1, which in turn activates the small G protein Ras. Ras goes on to activate a cascade involving Raf and MEK1/2, which then phosphorylates ERK1/2 MAPK, activating it. This cascade represents a novel pathway for endocytosis-mediated regulation of NCC. Certain heterotrimeric G proteins activate phospholipase C, releasing DAG and inositol 1,4,5-trisphosphate from the cell membrane, making G-coupled protein receptors expressed in the DCT such as the calcium-sensing receptor a likely possibility. In addition, any hormones with receptors in the DCT and effects on ERK1/2 are likely candidate hormones. Possible hormonal targets therefore include epidermal growth factor and aldosterone.

Here, we investigated a potential role of ubiquitin in the regulation of NCC via the ERK1/2 MAPK pathway and demonstrated that in both mDCT and transfected MDCK cells expressing FLAG-NCC, TPA administration causes a marked increase in ubiquitination (Fig. 5). This increase in ubiquitination is of a similar time course to the increase in internalized NCC as measured by the biotinylation/MesNa assay, suggesting a possible direct relationship between these findings (Fig. 5). We further investigated the role of ERK1/2 MAPK in the ubiquitination of NCC and showed that inhibiting ERK1/2 activation by either blocking MEK1/2 or gene silencing RasGRP1 prevented an increase in ubiquitinated NCC by TPA (Fig. 6). This clearly demonstrates that ERK1/2 phosphorylation is required for ubiquitination of NCC in a pathway starting with DAG/PE activation of RasGRP1.

By inhibiting ubiquitination of NCC via an E1 inhibitor, we were able to directly assess the role of ubiquitination in triggering endocytosis and therefore decreasing NCC activity in this system. Prevention of NCC ubiquitination eliminated any change in NCC surface expression with PE treatment (Fig. 7). ERK1/2 activation by TPA, however, remained intact, indicating that ERK1/2 MAPK alone is not sufficient for the usual observed DAG/PE effect on NCC (Fig. 7).

Ubiquitination of NCC has not been previously described, but ubiquitination has been demonstrated to play a role in the regulation of other transport proteins (11, 14, 15, 37). It is a highly conserved 76-amino acid polypeptide with an ever-growing list of cellular functions (32). Ubiquitin is covalently linked to its substrate by an isopeptide bond between its C-terminal glycine and the ε-amino group of lysine residues. This occurs via the actions of three enzymes. First, an ubiquitin-activating enzyme (E1) binds to ubiquitin before transfer to an ubiquitin-conjugating enzyme (E2). Next, the ubiquitin is transferred to the substrate protein with the aid of an ubiquitin ligase (E3), either by directly binding to the substrate from E2 in a reaction catalyzed by E3 or by forming an intermediate complex with E3.

In this system, the increase in NCC ubiquitination appears tied to ERK1/2 MAPK activation, but the actual mechanism by which this occurs is unclear, with a number of plausible mechanisms existing. These include direct phosphorylation of NCC (as is the case with ERK1/2 and ENaC), stimulation of an E3 ligase (described in many systems, such as regulation of the tumor suppressor protein p53), or inhibition of a DUB (1a, 2, 15, 20, 26, 28, 30, 31, 38). In addition to these possibilities, ERK1/2 enhancement of ubiquitination could be a multiple-step process, with ERK1/2 activating a second mediator which then acts on NCC, a ubiquitin ligase, or other regulatory protein. Of these prospective pathways, the simplest would be direct phosphorylation of NCC by ERK1/2, thereby enhancing the action of an E3 ligase and thereby enhancing ubiquitination. NCC, however, contains no traditional consensus sites for ERK1/2 MAPK phosphorylation. While noncanonical phosphorylation sites certainly are possible and the other mechanisms have not been explicitly demonstrated in ERK1/2 MAPK, this raises the likelihood that ERK1/2 may act via a different mechanism (25). Potential pathways involving E3 ligases, deubiquitinating enzymes, or other mediators provide attractive possible targets, and further work is merited to single out the possible effectors from the hundreds of E3 ligases, dozens of DUBs, and countless other kinases.

The lysine(s) on NCC to which ubiquitin attaches are unknown, and ubiquitination at these sites can carry unique regulatory implications (16). Similarly, the pattern of ubiquitination, be it monoubiquitination, polyubiquitination, or multubi ubiquitination, can play a key determinant in regulation. For instance, monoubiquitination, ubiquitination at a single site by a single ubiquitin, can signal endocytosis and lysosomal degradation, with epidermal growth factor receptor and other tyrosine kinase receptors being good examples (17). Polyubiquitination, where a ubiquitin attached to a target protein is itself ubiquitinated at one of its own lysines, often forming long polymerized chains of ubiquitin molecules, is well studied. The sites at which ubiquitin polymerizes have been correlated with the degradation pathway for the ubiquitinated protein (6, 22). Multiubiquitination, or monoubiquitination at multiple sites on the target protein, has also been described in other systems and can serve as a signal for endocytosis (1a, 15, 15a, 20, 26, 28, 31, 38).

In this study, we have demonstrated that NCC is endocytosed in response to PE administration. Furthermore, we describe that NCC is ubiquitinated and that this ubiquitination is essential for the regulation of NCC by PE. Activation of ERK1/2 MAPK by a pathway involving RasGRP1, Ras, Raf, and MEK1/2 is essential for DAG/PE-mediated ubiquitination to occur. This work represents the first description of endocytosis of NCC. It is also the first report of ubiquitination of this
cotransporter, and future study is warranted to further explore this means of NCC regulation.

ACKNOWLEDGMENTS

We thank Eugene Chang and Mark Musch for advice and discussions.

GRANTS

This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants K08 DK070668 (to R. S. Hoover) and K08 DK081728 (to B. Ko) and by grants from the Netherlands Organisation for Scientific Research NWO: 616.106.322 (to E.J. Kamsteeg) and 865.07.002 (to P.M.T. Deen). P.N. T. Deen is a recipient of VICI grant 865.07.002 from the Netherlands Organisation for Scientific Research.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

REFERENCES